Strategic partnerships Evox is actively engaging with external partners such as eXmoor Pharma Concepts and Rett Syndrome Research Trust to advance exosome-based delivery platforms, presenting ready-made collaboration and co-development opportunities for CDMO services, gene editing applications, and targeted therapeutics.

Exosome platform leverage With a modular exosome engineering platform and ExoEdit delivery technology, Evox offers a compelling entry point for partnerships in nucleic acid and protein delivery across neurodegenerative diseases and other genetically driven conditions, appealing to collaborators seeking innovative delivery solutions.

Financial footing Having raised substantial funding and reporting multi-million revenue ranges, Evox demonstrates financial capability to support joint development programs, technology transfers, and milestone-driven collaborations with pharmaceutical and biotech partners.

University-backed credibility Founding ties to Oxford University and Karolinska Institutet provide strong scientific credibility and access to leading exosome research, which can be leveraged in co-development proposals, grant-driven projects, and joint ventures with research institutions.

Expansion-ready capabilities Recent leadership changes and a cleared path for CEO transition, combined with a robust IP portfolio and manufacturing/purification know-how, position Evox to accelerate technology transfer deals, manufacturing collaborations, and scalable clinical translation opportunities.